NPM1突变急性髓系白血病:新的发病机制与治疗见解及开放性问题
NPM1突变约见于三分之一急性髓系白血病(AML),为AML特异,常涉及外显子12,并与FLT3-ITD、DNMT3A、TET2和IDH1/2突变相关。国际共识分类(ICC)和第五版世界卫生组织(WHO)髓系肿瘤分类均将其视为独立白血病实体。本文聚焦NPM1突变体在染色质层面的新功能及其驱动HOX/MEIS基因表达的相关性,讨论ICC/WHO分类中治疗相关NPM1突变AML的生物学与临床意义及原始细胞百分比定义的争议,并综述靶向NPM1/HLA新表位的CAR T细胞、XPO1抑制剂和menin抑制剂的治疗影响。
要点
- NPM1突变约见于三分之一AML,为AML特异,常涉及外显子12。
- NPM1突变AML在ICC和第五版WHO分类中均被视为独立白血病实体。
- NPM1突变体异常输出至白血病细胞胞质,并参与疾病发病机制。
核心结论
- NPM1突变AML在ICC和第五版WHO分类中均被视为独立白血病实体;本文讨论了NPM1突变体在染色质层面的新功能及其驱动HOX/MEIS基因表达的相关性,并综述了靶向NPM1/HLA新表位的CAR T细胞、XPO1抑制剂和menin抑制剂等新靶向治疗的影响。
研究设计与样本
- 综述,聚焦NPM1突变AML的发病机制与治疗进展。
主要发现
- NPM1突变约见于三分之一AML,为AML特异,通常涉及外显子12,常与FLT3-ITD、DNMT3A、TET2和IDH1/2突变相关。
- 所有NPM1突变均产生白血病突变体,异常输出至白血病细胞胞质,并与疾病发病机制相关。
- 本文聚焦NPM1突变体在染色质层面的新功能及其驱动HOX/MEIS基因表达的相关性。
关键数值与推荐
- NPM1突变AML在ICC和第五版WHO髓系肿瘤分类中均被视为独立白血病实体。
- ICC/WHO分类中治疗相关NPM1突变AML的生物学与临床意义及原始细胞百分比在定义NPM1突变AML中的相关性仍存争议。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The nucleophosmin (NPM1) gene encodes for a multifunctional chaperone protein that is localized in the nucleolus but continuously shuttles between the nucleus and cytoplasm. NPM1 mutations occur in about one-third of AML, are AML-specific, usually involve exon 12 and are frequently associated with FLT3-ITD, DNMT3A, TET2, and IDH1/2 mutations. Because of its unique molecular and clinico-pathological features, NPM1-mutated AML is regarded as a distinct leukemia entity in both the International Consensus Classification (ICC) and the 5th edition of the World Health Organization (WHO) classification of myeloid neoplasms. All NPM1 mutations generate leukemic mutants that are aberrantly exported in the cytoplasm of the leukemic cells and are relevant to the pathogenesis of the disease. Here, we focus on recently identified functions of the NPM1 mutant at chromatin level and its relevance in driving HOX/MEIS gene expression. We also discuss yet controversial issues of the ICC/WHO classifications, including the biological and clinical significance of therapy-related NPM1-mutated AML and the relevance of blasts percentage in defining NPM1-mutated AML. Finally, we address the impact of new targeted therapies in NPM1-mutated AML with focus on CAR T cells directed against NPM1/HLA neoepitopes, as well as XPO1 and menin inhibitors.
引用
- Falini B. NPM1-mutated acute myeloid leukemia: New pathogenetic and therapeutic insights and open questions. Am J Hematol. 2023. PMID: 37317978. doi:10.1002/ajh.26989
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。